High Emergence of ESBL-Producing E. coli Cystitis: Time to Get Smarter in Cyprus

Frontiers in Microbiology
Leon CantasTurgut Imir

Abstract

Widespread prevalence of extended-spectrum βeta-lactamase producing Escherichia coli (ESBL-producing E. coli) limits the infection therapeutic options and is a growing global health problem. In this study our aim was to investigate the antimicrobial resistance profile of the E. coli in hospitalized and out-patients in Cyprus. During the period 2010-2014, 389 strains of E. coli were isolated from urine samples of hospitalized and out-patients in Cyprus. ESBL-producing E. coli, was observed in 53% of hospitalized and 44% in out-patients, latest one being in 2014. All ESBL-producing E. coli remained susceptible to amikacin, carbapenems except ertapenem (in-patients = 6%, out-patients = 11%). High emerging ESBL-producing E. coli from urine samples in hospitalized and out-patients is an extremely worrisome sign of development of untreatable infections in the near future on the island. We therefore emphasize the immediate need for establishment of optimal therapy guidelines based on the country specific surveillance programs. The need for new treatment strategies, urgent prescription habit changes and ban of over-the-counter sale of antimicrobials at each segment of healthcare services is also discussed in this research.

References

Jan 1, 1995·Canadian Journal of Microbiology·M M DoolittleD E Caldwell
Feb 27, 2004·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R ColodnerR Raz
Sep 7, 2004·The Journal of Antimicrobial Chemotherapy·N WoodfordD M Livermore
Apr 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Emily P HyleEbbing Lautenbach
Jul 8, 2005·Microbiology·Harald Brüssow
Jul 12, 2005·The Journal of Antimicrobial Chemotherapy·D M Livermore, P M Hawkey
Oct 15, 2005·Clinical Microbiology Reviews·David L Paterson, Robert A Bonomo
Oct 26, 2005·Drugs & Aging·Florian M E WagenlehnerWolfgang Weidner
Nov 30, 2005·Comptes rendus biologies·Pascaline Lacroix-GueuMarie-Pierre Fontaine-Aupart
Sep 28, 2006·Pharmacy World & Science : PWS·Christos HadjimichaelEvros Demetriades
Dec 7, 2007·International Journal of Antimicrobial Agents·Hadi Mehrgan, Mohammad Rahbar
Dec 25, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R CantónT M Coque
Dec 25, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P M Hawkey
Dec 25, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D M LivermoreM Warner
Sep 22, 2009·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A EstebanezC Pérez Barba
Feb 13, 2010·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Rezan TopalogluDeniz Gur
Sep 3, 2010·Trends in Biotechnology·Mzia Kutateladze, Revaz Adamia
Oct 12, 2010·The Journal of Antimicrobial Chemotherapy·Ann Pallett, Kieran Hand
Aug 27, 2011·Current Opinion in Microbiology·Timothy K Lu, Michael S Koeris
Jan 12, 2012·Virology Journal·Irshad Ul HaqIshtiaq Qadri
Feb 16, 2012·Bacteriophage·Stephen T AbedonElizabeth Martin Kutter
Mar 28, 2012·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN Centers for Disease Control and Prevention, Public Health Service, U.S. Department Health
Jul 27, 2012·Frontiers in Microbiology·Eric C Keen
Sep 26, 2012·Antimicrobial Agents and Chemotherapy·Damien MauraLaurent Debarbieux
Nov 3, 2012·Journal of Virology·J TsonosH De Greve
Nov 15, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yohei DoiDavid L Paterson
Jan 15, 2013·International Journal of Microbiology·Sanna M SillankorvaJoana Azeredo
Jan 22, 2013·Trends in Biotechnology·Roberta J Worthington, Christian Melander
Mar 5, 2013·Applied and Environmental Microbiology·Felipe LiraSérgio R Nozawa

❮ Previous
Next ❯

Software Mentioned

Excel

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.